Breast Cancer Clinical Trials in North Carolina

Showing 161-180 of 619 trials

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Breast Carcinoma

University of Rochester NCORP Research Base1,363 participantsStarted Apr 2018

Honolulu, Hawaii, United States • Decatur, Illinois, United States • New Orleans, Louisiana, United States +15 more locations

RECRUITINGPhase 146 miles

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05783622

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck+4 more

Janux Therapeutics130 participantsStarted Apr 2023

Duarte, California, United States • Sacramento, California, United States • San Diego, California, United States +15 more locations

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Breast Cancer Trials in Other Cities

Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

Adaptation of a Values Assessment Tool

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Proton Radiation for Stage II/III Breast Cancer

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Other Conditions in North Carolina